Skip to main content
. 2019 Feb 13;9(2):e024655. doi: 10.1136/bmjopen-2018-024655

Table 2.

Incidence rates of osteonecrosis of the jaw (ONJ) and other characteristics in the enrolled study participants at the end of the 13-year follow-up period

Total Sjögren’s syndrome
With
Without P value
N (%) N (%) N (%)
Total 66 990 13 398 (20.00) 53 592 (80.00)
ONJ 28 (0.04) 11 (0.08) 17 (0.03) 0.017*
Gender 0.999
 Male 12 530 (18.70) 2506 (18.7) 10 024 (18.7)
 Female 54 460 (81.30) 10 892 (81.30) 43 568 (81.30)
Age (years) 59.63±17.54 57.40±16.88 60.19±17.66 <0.001*
Malignancy 10 825 (16.16) 1616 (12.06) 9209 (17.18) <0.001*
DM 9794 (14.62) 1292 (9.64) 8502 (15.86) <0.001*
Hypertension 10 984 (16.4) 2171 (16.20) 8813 (16.44) 0.506
CKD 2115 (3.16) 218 (1.63) 1897 (3.54) <0.001*
Osteoporosis 1268 (1.89) 425 (3.17) 843 (1.57) <0.001*
Bisphosphonates 6471 (9.66) 1454 (10.85) 5017 (9.36) <0.001*
Steroids 2775 (4.14) 2633 (19.65) 142 (0.26) <0.001*
Radiotherapy 46 (0.07) 4 (0.03) 42 (0.08) 0.063
Chemotherapy 526 (0.79) 152 (1.06) 384 (0.72) <0.001*

P value (categorical variable: χ 2/Fisher exact test; continuous variables: t test).

CKD, chronic  kidney disease; DM, diabetes mellitus.